Guselkumab, an IL-23 inhibitor, is effective in reducing signs, symptoms, and structural damage in active PsA, as confirmed by the APEX study. The FDA approved guselkumab in 2020 based on DISCOVER ...
Vulnerabilities created by insecure code could lead to data leakage or corruption, and the burden is on Salesforce customers to mitigate. Security researchers warn that many organizations have ...
PALO ALTO, Calif., Sept. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback